Clear Street Maintains Buy on Janux Therapeutics, Lowers Price Target to $32
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Clear Street analyst Kaveri Pohlman maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $80 to $32.
Clear Street analyst Kaveri Pohlman maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $80 to $32.